LDS/Medical Tests/Flurazepam, Urine

Flurazepam, Urine

Flurazepam belongs to the class of drugs known as Benzodiazepines. Benzodiazepines are a class of medications (drugs) that produce the following effects: sedation, hypnotic, muscle relaxant, antiemetic and anxiolytic. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS-depressants. Like all benzodiazepines, it acts by increasing the sensitivity of the GABAA receptor in the CNS to GABAA thereby opening the chloride channel allowing chloride to enter the neuron thereby making it negatively charged and more resistant to excitation.

Flurazepam is a short acting benzodiazepine and is primarily used as a hypnotic agent to treat insomnia. Flurazepam is a white crystalline powder that soluble in chloroform. Following an oral dose Flurazepam is rapidly metabolized to N-desalkylflurazepam and hydroxy-ethyl-flurazepam, which are the active metabolites. Metabolism occurs via the cytochrome P450 system in the liver. An accumulation of N-desalkylflurazepam in the blood after repeated doses produces a steady state condition after 7-10 days. Up to 60% of a flurazepam dose is eliminated in the urine within 48 hours. The primary urinary metabolite of flurazepam is hydroxy-ethyl-flurazepam glucuronide.

Flurazepam is one of the benzodiazepine class that is typically used by drug abusers. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine users. Benzodiazepines are only legally available through prescription. Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by immunoassays such as this test. Benzodiazepines can elicit the following paradoxical effects: antegrade amnesia, hostility, irritability, suicidal behavior and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death.

  • Therapeutic monitoring in serum
  • Drug abuse evaluation
  • Patient Compliance
A qualitative positive result from immunoassay (IA) screening type test indicates only the presence of any benzodiazepine such as flurazepam and is not specific and does not necessarily correlate with the extent of physiological and psychological effects. Any positive screening result must be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic concentration: < 30 ng/mL (in serum)

Toxic concentration: > 200 ng/mL (in serum)

 

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

 

Cut-Off Ranges

Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as TLC, or IA, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

 

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of detection is via LC/MS. This particular method of analysis is used to not only detect the parent drug compound, Flurazepam, but also the major metabolites of flurazepam. These active metabolites should be quantified to assess the overall concentration of flurazepam. Flurazepam, as well as all benzodiazepines, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis, since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Urine

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 7 days
  • Refrigeration: 30 days
  • Frozen: 180 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19 may be tested for drug safety and efficacy before prescribing. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Barry Levine (Ed.). AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC (ed.). Disposition of Tox Drugs and Chemicals in Man, Sixth Edition, Biomedical Publications, Foster City, CA (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.